Search results
Hace 5 horas · May 23 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's (GH.O) , opens new tab blood test to detect a cancer that begins ...
Hace 3 horas · By Puyaan Singh and Leroy Leo. (Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins ...
Hace 1 hora · By Puyaan Singh and Leroy Leo. London: Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health 's blood test to detect a cancer that begins in ...
Hace 6 horas · May 23 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum. The panel voted seven-to-two in favor of benefits outweighing risks when using the test called Shield for colorectal cancer.
Hace 3 días · The U.S. Food and Drug Administration's staff reviewers on Tuesday raised concerns that Guardant Health's experimental blood test for a cancer of colon or rectum may fail to detect some types of tumors that can later become cancerous. The comments come ahead of Thursday's meeting of the FDA's outside advisers, who are expected to provide non-binding recommendations to the agency.
Hace 4 días · May 20, 2024 at 10:35 AM. (Reuters) -The U.S. Food and Drug Administration on Monday approved two close copies of Regeneron Pharmaceuticals' blockbuster eye drug, Eylea, potentially hurting the ...
Hace 4 días · Brian Kilmeade Show. (Reuters) - The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster eye drug Eylea, according to information on the agency's website. (Reporting by Leroy Leo in Bengaluru; Editing...
